ガイドライン

(旧版)前立腺癌診療ガイドライン 2006年版

書誌情報
第2章 診断

 
参考文献

1) Chodak GW: Early detection and screening for prostatic cancer. Urology. 1989;34:10-2.
2) Pedersen KV, Carlsson P, Varenhorst E, et al. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ. 1990;300:1041-4.
3) Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen(PSA)in the early detection of prostate cancer:results of a multicenter clinical trial of 6630 men. J Urol. 1994;151:1283-90.
4) Haas GP, Monyie JE, Pontes JE. The state of prostate cancer screening in the United States. Eur Urol. 1993;23:337-47.
5) Gretzer MB, Partin AW:PSA markers in prostate cancer detection. Urol Clin North Am. 2003;30(4):677-86.
6) Okihara K, Cheli CD, Partin AW, et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol. 2002;167:2017-23.
7) Elgamal AA, van Poppel HP, van de Voorde WM, et al. Impalpable, invisible stage T1c prostate cancer:characteristics and clinical relevance in 100 radical prostatectomy specimens--a different view. J Urol. 1997;157:244-50.
8) Gustafsson O, Norming U, Almgard LE, et al. Diagnostic methods in the detection of prostate cancer:a study of a randomly selected population of 2,400 men. J Urol. 1992;148:1827-31.
9) Mettlin C, Murphy GP, Babaian RJ, et al. The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer. 1996;77:150-9.
10) Punglia RS, D’Amico AV, Catalona WJ, et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 2003;349(4):335-42.
11) Hodge KK, McNeal JE, Terris MK et al. Random systemamic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989;142:71-4.
12) Emiliozzi P, Corsetti A, Tassi B, et al. Best approach for prostate cancer detection:a prospective study on transperineal versus transrectal six-core prostate biopsy. Urology. 2003;61(5):961-6.
13) Emiliozzi P, Longhi S, Scarpone P, et al. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J Urol. 2001;166(3):845-50.
14) Raaijmakers R, Kirkels WJ, Roobol MJ, et al. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology. 2002;60(5):826-30.
15) Babaian RJ, Toi A, Kamoi K, et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000;163(1);152-7.
16) Presti JC Jr, Chang JJ, Bhargava V et al. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies:result of a prospective clinical trial. J Urol. 2000;163(1):163-6;discussion 166-7.
17) Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen lvalues. J Urol. 1994;151:1571-4.
18) Roerhborn CG, Pickers GJ, Sanders JS. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnosis and prostate specific antigen levels. Urology 1996;47:347-52.
19) Zlotta AR, Raviv G, Schulman CC. Clinical prognostic criteria for later diagnosis of prostate carcinoma in patients with initial isolated prostatic intraepithelial neoplasia. Eur Urol. 1996;30(2):249-55.
20) Haggman MJ, Macoska JA, Wojno KJ, et al. The relationship between prostatic intraepithelial neoplasia and prostate cancer:critical issues. J Urol. 1997;158(1):12-22.
21) Spigelman SS, McNeal JE, Freiha FS, et al. Rectal examination in volume determination of carcinoma of the prostate:clinical and anatomical correlations. J Urol. 1986;136:1228-30.
22) Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms(Partin Tables)for the new millennium. Urology, 2001;58:843-8.
23) Rorvik J, Halvorsen OJ, Servoll E, et al. Transrectal ultrasonography to assess local extent of prostatic cancer before radical prostatectomy. Br J Urol. 1994 73:65-9.
24) Lee N, Newhouse JH, Olsson CA, et al. Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients. Urology 1999;54:490-4.
25) Jager GJ, Severens JL, Thornbury JR, et al:Prostate cancer staging:should MR imaging be used?--A decision analytic approach. Radiology. 2000;215:445-51.
26) Heenan SD. Magnetic resonance imaging in prostate cancer. Prostate Cancer Prostatic Dis. 2004;7:282-8.
27) Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110-4.
28) Whitmore WF Jr:Natural history and staging of prostate cancer. Urol Clin North Am. 1984;11:205-20.
29) Gerber G, Chodak GW. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer. Urology. 1991;37:418-22.
30) Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61:195-202.
31) Rana A, Karamanis K, Lucas MG, et al. Identification of metastatic disease by T category, gleason score and serum PSA level in patients with carcinoma of the prostate. Br J Urol. 1992;69:277-81.
32) Oesterling JE. Prostate specific antigen:a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145:907-23.
33) Oesterling JE. Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications. Urol Clin North Am. 1993;20:705-11.

書誌情報